1. Home
  2. APRE vs REED Comparison

APRE vs REED Comparison

Compare APRE & REED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.59

Market Cap

10.8M

Sector

Health Care

ML Signal

N/A

Logo Reed's Inc.

REED

Reed's Inc.

N/A

Current Price

$0.64

Market Cap

9.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
APRE
REED
Founded
2006
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
9.1M
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
APRE
REED
Price
$0.59
$0.64
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $3.73
N/A
AVG Volume (30 Days)
★ 216.9K
142.8K
Earning Date
11-11-2026
08-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 21.22
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $34,065,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$27.29
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.55
$0.56
52 Week High
$1.69
$5.97

Technical Indicators

Market Signals
Indicator
APRE
REED
Relative Strength Index (RSI) 31.60 38.60
Support Level N/A $0.63
Resistance Level $0.81 $0.94
Average True Range (ATR) 0.06 0.06
MACD -0.02 0.01
Stochastic Oscillator 12.15 45.25

Price Performance

Historical Comparison
APRE
REED

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

Share on Social Networks: